A prospective phase II trial, European Organization for Research Treatment of Cancer (EORTC) 90101 “CREATE”, evaluated the oral MET/ALK/ROS1 inhibitor crizotinib in patients with CCSA [11]. This evidence concerns the gene MET and cancer.